G-4527

Celecoxib Enhances Tolerogenic Signaling in Human Dendritic Cells via STAT3 and IDO Pathways

 Mahya Zolfaghar Ghshooni ¹ ℗, vida hashemi ², Arezoo Hosseini ³ ©   

 
Abstract

Introduction: Tolerogenic dendritic cells (DCs) contribute to immune regulation by promoting anti-inflammatory cytokines and regulatory T cell responses. Celecoxib, a COX-2 inhibitor, may influence DC tolerogenic pathways, but its molecular impact is not fully understood. Objective: To evaluate the role of Celecoxib in promoting tolerogenic signaling in monocyte-derived DCs, focusing on anti-inflammatory mediators and regulatory pathways. Methods and Materials: Human moDCs were treated with 5 µM Celecoxib. Expression of IL-10, TGF-β, STAT3, and IDO was quantified using real-time PCR. Morphological integrity and surface markers were validated by flow cytometry. Results: Celecoxib significantly increased IL-10 (P0.01), TGF-β (P0.05), STAT3 (P0.01), and IDO (P0.01) expression. STAT3 activation correlated with reduced pro-inflammatory cytokines and enhanced tolerogenic signaling. Conclusion and Discussion: Celecoxib promotes a tolerogenic phenotype in moDCs by upregulating STAT3 and IDO, highlighting its potential as an immunomodulatory agent in autoimmune and inflammatory conditions.

Keywords: Dendritic cells, Monocyte-derived DCs, Celecoxib, COX-2 inhibition, Cytokine modulation, Anti-inflammatory